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β-Hairpin mimics containing a piperidine-pyrrolidine scaffold modulate the 
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Alzheimer’s disease is a neurodegenerative disorder linked to oligomerization and fibrillization of amyloid β peptides, with 
Aβ1-42 being the most aggregative and neurotoxic one. We report herein the synthesis and conformational analysis of Aβ1-42 
-amyloid related β-hairpin peptidomimetics, built on a piperidine-pyrrolidine semi rigid β-turn inducer and bearing two 
small recognition peptide sequences, designed on oligomeric and fibril structures of Aβ1-42. According to these peptide 
sequences, a stable β-hairpin or a dynamic equilibrium between two possible architectures was observed. These original 
constructs are able to greatly delay the kinetics of Aβ1-42 aggregation process as demonstrated by thioflavin-T fluorescence, 
and transmission electron microscopy. Capillary electrophoresis indicates their ability to preserve the monomer species, 
inhibiting the formation of toxic oligomers. Furthermore, compounds protect against toxic effects of Aβ on neuroblastoma 
cells even at substoichiometric concentrations. This study is the first example of acyclic small β-hairpin mimics possessing 
such a highly efficient anti-aggregation activity. The protective effect is more pronounced than that observed with 
molecules which have undergone clinical trials. The structural elements made in this study provide valuable insights in the 
understanding of the aggregation process and insights to explore the design of novel acyclic β-hairpin targeting other 
types of amyloid-forming proteins. 
Introduction 
Amyloid fibrils are self-assembled insoluble aggregates 
characterized by highly ordered cross-β structures. They constitute 
the hallmark of more than 20 serious human amyloidosis diseases, 
such as Alzheimer’s disease (AD), Parkinson’s neurodegeneration, 
type II diabetes and spongiform encephalopathy.
1
 In particular, AD 
is associated with the aggregation of the amyloid-β (Aβ1-42) peptide 
into senile plaques in the brain.
2
 A large number of small molecules 
have been proposed for their ability to inhibit or modulate Aβ1-42  
aggregation and toxicity. However, the aggregation process is highly 
complex, and extremely difficult to control.
3
 Fibrils are able to 
generate damaging redox activity and promote the nucleation of 
toxic oligomers.
4
 Recent studies indicate that soluble transient 
oligomers preceding fibril formation are highly toxic species.
5
 Their 
characterization and the activity of Aβ1-42 aggregation inhibitors on 
these small and toxic oligomeric species is generally lacking. Thus, 
the development of inhibitors targeting both oligomerization and 




Peptides are today reasonable alternatives to small molecule 
pharmaceuticals. They often offer greater efficacy, selectivity, 
specificity and a reduced risk of unforeseen side‐reactions 
compared to small organic molecules, while some of their 
pharmacodynamic weaknesses can be circumvented by innovative 
formulations.
6
 A variety of small peptides that inhibit aggregation of 
Aβ and reduce its toxic effects have been already described.
7
 In 
particular, inhibition of Aβ-aggregation has been targeted using 
self-recognition elements (SREs). Indeed, molecules based on 
fragments of the Aβ-peptide, essentially on the nucleation 
sequence Aβ16−20 (KLVFF), were found promising as SREs.
8
 The 
design of macrocycles β-sheet mimics containing an unnatural 
tripeptide unit (Nowick’s Hao) and SREs, has been a valid strategy.
9
 
To our knowledge, the use of small acyclic -hairpins has been very 
rarely explored as -sheet binders and inhibitors of aggregation.
10
  
Interestingly, compounds possessing several kinetically and 
thermodynamically accessible local minima representing 
conformations might be much more powerful inhibitors with 
respect to rigid ones in modulating protein-protein interactions.
11
 
As Aβ-aggregation is a dynamic and complex process, we 
hypothesized that flexible -hairpins could adapt themselves in the 
interaction with the different Aβ1-42 conformations present during 
the aggregation process, and in particular in the early stages of 
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oligomerization. For that purpose, we designed two acyclic, β-
hairpin mimics G1 and G2 based on the piperidine-pyrrolidine semi-
rigid scaffold S1,
12
 developed recently as a flexible β-turn inducer 
(Figure 1), and on different SREs of Aβ1-42. The nucleation sequence 
Aβ16−20 (KLVFF) has been introduced in the C-terminal sequence of 
both G1 and G2. However, the choice of the N-terminal sequence 
was driven by the strategy to develop both a flexible and a more 
structured β-hairpin. The hydrophobic sequence G33LMVG37, facing 
K16LVFF20 in the more flexible oligomeric structures
13
 has been 
introduced in G1. In G2, GVVIE has been chosen as a mimic of the 
hydrophobic sequence G38VVIA42, facing K16LVFF20 in the stable fibril 
structures.
14
 The alanine residue has been replaced by glutamic acid 
in order to possibly engage an ionic interaction with the facing 
lysine residue, thus stabilizing the β-hairpin structure (Figure 1). The 
N-terminal amino acid of both G1 and G2 was either acetylated 
(G1a, G2a) or not (G1b, G2b), in order to evaluate the capacity of 
the compounds to engage electrostatic interactions with acidic 
residues of Aβ1-42 and with the view to increase their affinity. 
Several computational and experimental studies on Aβ1-42 proved in 
fact that, in addition to the hydrophobic interactions involving in 
particular the 16-21 sequence (KLVFFA), the formation of a salt-
bridge between amino acids Asp23 and Lys28 of amyloid might 
stabilize a turn motif involving residues 24-28.
13
 An interaction with 




































Figure 1. Structure of β-amyloid mimics G1 and G2 and the 
corresponding SREs 
 
Results and discussion 
Conformational studies and synthesis. In order to evaluate the 
folding propensity of the designed G1 and G2 β-hairpin mimics, as 
well as to get preliminary information on their conformational 
stability, we performed a computational study using replica 
exchange molecular dynamics (REMD) on G1a and G2a.
16,17,18
 Thus, 
we simulated peptides G1a and G2a using the ff96 force field 
coupled with the OBC(II) solvent model,
19
 (see Supporting 
Information (SI) for additional details). The secondary structure 
analysis by DSSP
20
 (Tables S1 and S2, SI) showed that both peptides 
have a relatively high tendency to form anti-parallel β-sheets. G2a 
seemed to form a very stable β-hairpin, with percentage values of 
anti-parallel β-sheet content, relatively to non-terminal amino 
acids, ranging from about 60 to about 90%. G1a was somehow less 
stable, with an anti-parallel β-sheet content averagely 20% less than 
G2a. In the H-bond analyses (Tables S3 and S4, SI) two pairs of very 
stable H-bonds, involving the backbone NH and C=O atoms of 
residues Ile4/Leu8 and Val2/Phe10, were observed for G2a. On the 
other hand, the occupancies of intramolecular H-bonds detected 
for G1a were lower. We observed a minor populated hairpin 
conformation, characterized by the H-bonds involving Val4/Leu8 
and Leu2/Phe10, and a major “mismatched” hairpin involving 
Val4/Val9 and Leu2/Phe11. The representative structures of the 
most populated cluster for G1a and G2a (Figure 2) showed a 
mismatched β-hairpin for the former peptide, with the N-terminal 
strand (Gly1-Gly5) that was shifted one residue with respect to the 
C-terminal strand (Lys7-Phe11). Conversely, for G2a, the two 
strands were perfectly matched. The higher conformational 
flexibility of G1a, compared to G2a, was also shown by the root 
mean square deviation (RMSD) analysis of the corresponding REMD 
trajectories (Figure S1, SI), confirming the possibility of an 
equilibrium for the former peptide between multiple β-hairpin like 
conformations, while a single and fairly rigid β-hairpin conformation 
was predicted for G2a. 











Figure 2. Representative structures of the most populated cluster 
obtained from cluster analyses of the 302.76 K trajectory of REMD 
simulations for peptides G1a (left) and G2a (right).  
 
Compounds G1 and G2 were thus prepared by solid phase peptide 
synthesis, using the Fmoc strategy (see SI for details).
21 
In order to 
evaluate the efficacy of G1 and G2 molecules with respect to a 
truncated derivative or the single arms, we also prepared derivative 
G3 (Figure 3), containing the scaffold and only the Aβ(16−20) SRE, 
and compounds SRE1-3 corresponding to the different SREs (Figure 











Figure 3. Structure of truncated mimic G3 
 
The CD spectra of G1a and G2a were recorded in MeOH at 25 
°C (Figure 4). G1a showed a negative band at 195 nm 
indicating that in solution this peptidomimetic did not assume 
a preferred, single conformation. On the other hand, the 
spectrum of G2a was characterized by a strong positive Cotton 
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effect at around 195 nm (π-π* energetic transition), and a 
negative band at around 215 nm (n-π* energetic transition), 
typical of β-sheet structures.  
 
Figure 4. CD spectra of compounds G1a and G2a in MeOH 
 
The different behaviour of G1a and G2a was confirmed by 
1
H-NMR 
experiments in CD3OH (Tables S6-S8 in SI). Compound G1a is 
present in solution as two different -hairpin structures (G1a-
1/G1a-2, 2:1 ratio, Figure 5), characterized by a different alignment 
of the two peptide arms. This dynamic equilibrium is proved by the 





H NMR spectrum of G2a showed a good dispersion of 
the NH chemical shifts indicating the presence of a stable single -
hairpin conformation characterized by a peptide arms alignment 






































































































































































Figure 5. β-Hairpin structures of compounds G1a-1, G1a-2, and 
G2a, showing the assigned ROEs  
ROESY experiments confirmed the presence of a turn structure in 
G1a-1, G1a-2, and G2a, as already reported for model sequences 
(Figure S5 and Figure S11, SI).12a  
Several
 
sequential CH/NH ROEs, indicating β-conformations, were 
found for both G1a-1 and G1a-2 isomers (Figures 5 and S6, SI). The 
different alignment of the peptide chains was proven by a ROE 
between NHPhe11/CHMet3 in G1a-1, and by another one between 
NHLeu2/CHVal9 in G1a-2 (for a complete discussion see SI)  
Regarding compound G2a we could detect only one β-hairpin 
diagnostic ROE between CHGly1 and the phenyl ring of Phe-10 
(Figures 5 and S12, SI). Several CH signals are indeed overlapped 
or masked by the solvent. The presence of a β-hairpin structure was 
confirmed by 
3
JHN/CH coupling constants that are higher than 8 
Hz (Table TS9, SI).
24,25 
Finally, the β-hairpin conformation was definitively confirmed for all 
compounds by the positive difference between experimental Hα 
chemical shift values and “random” ones
26
 (Figure 6). Only Met-3 of 
G1a-1 is characterized by a negative H value. This is probably 
due to the anisotropic effect
27
 of the aromatic ring of Phe-11 that 
faces Met-3, as evicted from ROESY experiments (Figure S6A, SI). 
 
Figure 6. NMR analysis. Plot of difference between Hα chemical 
shift values in the random coil and the values determined 
experimentally for G2a (blue) and isomers G1a-1 (red) and G1a-2 
(green) in CD3OH at 298 K. 
Taking together both experimental and theoretical results, we can 
conclude that different hairpin architectures are possible for G1a 
and G2a, depending on the N-terminus sequence. The GVVIE motif 
in G2a strongly stabilizes a single “matched” hairpin conformation. 
On the other hand, the GLMVG motif in G1a gave a dynamic 
equilibrium between two possible architectures, the “mismatched” 
hairpin being the more stable.  
 
Inhibition of Aβ1-42 fibrillization. The ability of compounds G1-3 and 
SRE1-3 to interact with Aβ1-42 during the fibrillation process was first 
studied by Thioflavin-T (ThT) fluorescence spectroscopy.
28
 The 
fluorescence curve for Aβ1-42 at a concentration of 10 µM followed 
the typical sigmoid pattern with a lag phase of 4-5 h followed by an 
elongation phase and a final plateau reached after 10-12 h (Figure 
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alone and in the presence of the evaluated compound: (1) t1/2, is 
defined as the time at which the half maximal ThT fluorescence is 
observed, which gives insight on the rate of the aggregation 
process; (2) the fluorescence intensity at the plateau (F) which is 
assumed to depend on the amount of fibrillar material formed 
(Table 1).  
Both G1 and G2 series are able to inhibit Aβ1-42 aggregation. The G1 
series, containing the sequence G37VMLG33, and possessing a 
dynamic equilibrium between two different β-hairpin 
conformations, exerts a slightly superior inhibitory activity (Figure 7 
and Table 1). Furthermore, the free terminal amine is also 
important for Aβ1-42 aggregation suppression. Unprotected G1b and 
G2b were indeed able to totally suppress aggregation at 
compound/ Aβ1-42 ratio of 10/1 and still dramatically delayed Aβ1-42 
aggregation at 1/1 ratio (Figure 7a) and Table 1). Acetylated 
derivatives G1a and G2a retained this activity, but to a lesser extent 
(Table 1 and Figure S14). This result supports our hypothesis on the 
importance of establishing an ionic interaction between the N-
terminal amino group and acidic residues of Aβ1-42.  
No activity was observed for the isolated pentapeptides GLMVG 
(SRE1) and GVVIE (SRE2) (Table S11 and Figure S14). KLVFF (SRE3) 
delayed Aβ1-42 aggregation at compound/ Aβ1-42 ratio of 10/1,
8a,29
 
however in a much lesser extent than G1 and G2 series, while 
exerted no activity at 1/1 ratio (Table S11). The G3 intermediate 
containing KLVFF linked to the piperidine-pyrrolidine scaffold S1 is 
more active than SRE3. These results highlight that the piperidine-
pyrrolidine scaffold S1 and the pentapeptide KLVFF are both crucial 
for the activity, but the whole β-hairpin construct is necessary to 
strongly delay the Aβ1-42 aggregation kinetics.  
 
 
Figure 7. a) Representative curves of ThT fluorescence assays over 
time showing Aβ1-42 (10 µM) aggregation in the absence (purple 
curve) and in the presence of compounds G1b (red curves) and G2b 
(blue curves) at compound/Aβ1-42 ratios of 10/1 and 1/1. The 
control curves are represented in dotted lines (G1b in red, G2b in 
blue and grey for buffer). Fibril formation of Aβ1-42 visualized by 
TEM: negatively stained images recorded after 42 h of incubation of 
Aβ1-42 (10 µM in 10 mM Tris.HCl, 100 mM NaCl at pH = 7.4) alone (b) 
or in the presence of 10 µM of G1b (c) or G2b (d). Scale bars 
represent 500 nm.  
 
Table 1. Effects of compounds G1-2 on Aβ1-42 fibrillization assessed 
by ThT-fluorescence spectroscopy at 10/1 and 1/1 compound/Aβ 
ratios (the concentration of Aβ1-42 is 10 M) and compared to the 













G1a (10/1) NA –97±1% 
G1a (1/1) 2.06±0.12 –71±2% 
   
G2a (10/1) Sat [c] Sat [c] 
G2a (1/1) 1.76±0.11 –41±7% 
   
G1b (10/1) NA –97±1% 
G1b (1/1) NA –90±2% 
   
G2b (10/1) NA –95±1% 
G2b (1/1) >3.56±0.12 –73±3% 
NA = no aggregation, parameters are expressed as mean ± SE, n=3-6. [a] See SI 
for the calculation of the t1/2 extension. A compound displaying a t1/2 increase > 1 
is a delayer of aggregation. [b] See SI for the calculation of the change of 
fluorescence intensity at the plateau. [c] Sat means that a saturation of the 
fluorescence signal is observed because G2a self-aggregates at 100 M. 
 
In order to assess the selectivity on A1-42 peptide, the ability of 
compounds G1b and G2b to interact with IAPP (islet amyloid 
polypeptide), an amyloid protein involved in type 2 diabetes 
mellitus but having another SRE,
30
 was also tested by the ThT-
fluorescence assay under conditions similar to that described for 
A1-42 peptide. It is noteworthy that both compounds displayed no 
activity on IAPP fibrillization process at compound/Aβ1-42 ratio of 
1/1 and only slightly delayed it at the higher ratio (10/1) (Figure 
S15). This result suggests that the inhibition of aggregation 
displayed by compounds G1b and G2b on A1-42 peptide is sequence 
specific. 
Transmission electron microscopy (TEM) analyses were performed 
on the most promising G1a, G1b and G2b compounds. Images were 
recorded at 20 h and 42 h of fibrillization kinetics with samples 
containing 10 µM of each compound corresponding to the 
compound/Aβ1-42 ratio of 1/1 (Figures 7b)-d) and S16). Differences 
were observed in both quantity and morphology of aggregates 
formed. At 42 h, a very dense network of fibers displaying a typical 
morphology was observed for Aβ1-42 alone (Figure 7b). In the 
samples containing G1a, the network of fibers was significantly less 
dense than in the control experiment after 20 h and 42 h. However, 
the fibers displayed the same morphology (Figure S16, SI). In the 
samples containing G2b, the same trends as with G1a were 
observed (Figures 7d and S16). In samples containing G1b, we 
mainly observed globular aggregates after 20 h and 42 h (Figures 
7c) and S16) indicating that the aggregation pathway could be 
G2b / Aβ1-42 (1/1)
G1b / Aβ1-42 (1/1)
G2b / Aβ1-42 (10/1)
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different from the one observed for Aβ1-42 alone. These results 
validated the ThT-fluorescence data, indicating that compounds 
G1a, G1b and G2b dramatically slowed down the aggregation of 
Aβ1-42 and efficiently reduced the amount of typical amyloid fibrils. 
 
Inhibition of Aβ1-42 oligomerization. Compounds G1b and G2b were 
finally studied (at compound/Aβ1-42 ratio of 1/1) by Capillary 
Electrophoresis (CE) using a method we recently proposed to 
monitor the very early steps of the oligomerization process 
overtime and to analyze the effect of drugs on these challenging 
first stages.
31
 We focused our attention on three kinds of species: 
(1) the monomer (peak ES), (2) different small metastable oligomers 
grouped under peak ES
I
 and (3) transient species formed later and 
which correspond to species larger than dodecamers but still 
soluble (peak LS). Aggregation kinetics of Aβ1-42 peptide alone 
(Figures 8a and S18) showed that overtime, the monomer ES peak 
decreased in favor of the oligomer peaks ES
I
 and LS, and that 



































Figure 8. Electrophoretic profile obtained immediately (0 h, 
red), 8 h (blue) and 24 h (purple) after sample dissolution of 
Aβ1-42 peptide (100 µM) a) alone or b) in the presence of G1b 
(100 µM). c) Peak area of the monomer (ES) related to its peak 
area in the sample of Aβ1-42 alone at 0h. 
 
In the presence of G1b, the aggregation kinetics of Aβ1-42 peptide 
was greatly modified (Figures 8b and S19). Noteworthy, the 
monomeric species (peak ES) was dramatically stabilized. 86% of 
the monomer remained after 24 h in the presence of G1b, while it 
was no more detected in the control sample (Figure 8c). Moreover, 
the larger aggregated species LS (> dodecamers) were not detected. 
New aggregated forms of Aβ1-42, between ES’ and LS migration 
times were observed on each electrophoretic profile. We checked 
that these new aggregated forms were not due to G1b degradation 
or self-assemblies (Figure S17A.) They were probably aggregated 
forms with a different morphology than both LS and those giving 
spikes observed in Aβ1-42 control. This observation is in accordance 
with the TEM images where globular aggregates were observed 
instead of the classical dense network of fibers (Figures 7c and S16). 
In ThT-assays, no fluorescence was detected, indicating that the 
globular species were not characterized by highly ordered β-
structures (Figure 7a). Remarkably, the presence of the monomer 
was maintained even after 4 days (Figure S19B). We concluded that 
G1b is able to prevent the formation of toxic soluble oligomers of 
Aβ1-42 peptide and to maintain the presence of the non toxic 
monomer overtime.  
G2b also dramatically maintained the presence of the 
monomer (peak ES, 80% after 24 h, Figures 8c, S20 and S21). 
However, new aggregated forms were only transiently 
observed but were not anymore detected after 24h. This result 
was also in accordance with the TEM images where we 
observed a much less dense network of fibers, although the 
typical morphology was retained. 
 
Protection against Aβ1-42 cell toxicity. The inhibitors were 
investigated to determine their ability to reduce the toxicity of 
aggregated Aβ1-42 to SH-SY5Y neuroblastoma cells. The addition of 
all compounds, to a lesser extent for G2b, showed a protective 
effect on cell survival (MTS assay, Figure 9) and membrane damage 
(LDH membrane integrity assay, Figure 10) in the presence of 
cytotoxic 5 µM Aβ1-42. Remarkably, this protective effect was seen 
at equimolar amounts of inhibitor to Aβ1-42 and was still significant 
at a very low ratio of 0.1/1 (inhibitor/Aβ1-42) in the MTS assay. Both 
G2a and G1b showed a slight negative effect on cell viability when 
incubated with cells alone, although this was negated when Aβ was 
present.  
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Figure 9. Cell viability assay results. The solid line represents the 
absorbance value seen for cells incubated without Aβ1-42 (white 
box) and the dotted line that seen for cells incubated with 5µM Aβ1-
42 (grey box). A statistically significant difference between Aβ1-42 
treated cells with and without inhibitor is indicated by */**/*** 








































































































































































































































































































* * * * * * * * * * * * * * * * * * * * * *
Figure 10. LDH based cell toxicity test. Cells were treated in the 
same manner as with the MTS assay, and cell proliferation was 
measured  using the CytoTox 96® NonRadioactive Cytotoxicity Assay 
Protocol from Promega. Statistical analysis was performed using a 
student’s t test comparing the results for cells exposed to 5 µM Aβ1-
42 with and without inhibitor where ** = p<0.01 and *** = p<0.001. 
 
This protective effect is more marked than that observed with 
molecules which have undergone clinical trials
32,33,34 
or other 
molecules recently described as efficient reducers of Aβ1-42 
toxicity.
35
 In particular, in the literature, resveratrol was 
reported to protect SH-SY5Y neuroblastoma cells from Aβ1-42 
toxicity at 10/1 and 2/1 (resveratrol/Aβ1-42) ratios,
32
 scyllo-
Inositol was demonstrated to protect PC-12 cells at 10/1 ratio 
(scyllo-inositol/Aβ1-42),
33
 and (−)-epigallocatechin-3-gallate 
(EGCG) protected murine neuro-2a neuroblastoma cells at 1/1 
ratio (−)-epigallocatechin-3-gallate/Aβ1-42).
34
 In our hands, and 
comparable to the published data,
32
 resveratrol efficiently 
protected SH-SY5Y neuroblastoma cells only at a ratio of 2/1 
(resveratrol/Aβ1-42). A stoichiometric ratio 1/1 was less 
efficient than a substoichiometric ratio of G1b and G2b (0.5/1 
compound/ Aβ1-42) (Figure 11). Resveratrol exhibits multi-
target activity and thus is not selective for Aβ1-42 aggregation. 
For example, resveratrol inhibits similarly the aggregation of 
other amyloid proteins such as IAPP
36
 (EGCG also inhibits 
similarly Aβ1-42 and IAPP aggregation in ThT fluorescence 
assays
37,38
), which is not the case for G1b and G2b, as 
mentioned above. By choosing the SREs in our β-hairpin 
mimics, specifically according to the target amyloid proteins, 
we can modulate the activity and expect selective activities.  
 
 
Figure 11. Cell viability assay results of resveratrol compared to G1b 
and G2b. The solid line represents the mean absorbance value seen 
for cells incubated without Aβ1-42 (white box) and the dotted line 
that seen for cells incubated with 5µM Aβ1-42 (grey box). A 
statistically significant difference between Aβ1-42 treated cells with 
and without inhibitor is indicated by */**/*** corresponding to 
p>0.05/0.01/0.001. n=4 for each condition. 
 
CONCLUSION 
We described new β-hairpin mimics designed on oligomeric 
and fibril structures of Aβ1-42 and containing a piperidine-
pyrrolidine β-turn inducer. The presence of two small 
recognition sequences able to engage both hydrophobic and 
ionic interactions with Aβ1-42, dramatically increased the 
inhibitory effect on the fibrillization process. Furthermore, the 
presence of the semi-rigid piperidine-pyrrolidine scaffold S1 
and of the hydrophobic sequence G33LMVG37, which allows a 
dynamic equilibrium between different architectures, leads to 
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the obtainment of compound G1b able to inhibit totally the 
formation of amyloid fibrils. As far as we know, this study is 
the first example of acyclic small β-hairpin mimics possessing 
such a highly efficient anti-aggregation activity. This activity is 
much higher than isolated SREs described in the literature. 
Furthermore, to the best of our knowledge, this is the first 
example of compounds able to dramatically preserve the non 
toxic monomer species of Aβ1-42. This result might explain the 
mechanism by which β-hairpin mimics exhibit a strong 
protective effect on cells even at substoichiometric 
concentrations. The structural elements made in this study 
provide valuable insights to explore the design of novel acyclic 
β-hairpin targeting other types of amyloid-forming proteins. 
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